Altria
MO
69.38
+0.83
+1.21%
Altria
US · MO
#178 by market cap
Listed 1970
69.38
+0.83
+1.21%
Live - 5344 symbols - heartbeat 8s ago
· 2026-10-08 08:19
Pre-market
69.70
+0.46%
After-hours
69.35
-0.04%
Overnight
69.55
+0.25%
- Market cap
- 115.85B
- P/E (TTM)i
- 14.61
- P/Bi
- -43.42
- EPSi
- 4.12
- Div yieldi
- 6.11%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on MO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.91, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -3.08% YoY
Margins
- Gross margin
- 72.21%
- Operating margin
- 59.76%
- Net margin
- 34.40%
Key ratios & quality
- Enterprise valuei
- 137.08B
- PEG ratioi
- 2.27
- Altman Z-Scorei
- 4.91
PEG uses trailing P/E against the 3-year net income growth rate (6.42%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25.36B | 25.11B | 26.15B | 26.01B | 25.10B | 24.48B | 24.02B | 23.28B |
| Gross profit | 12.25B | 12.71B | 13.02B | 13.99B | 14.25B | 14.28B | 14.37B | 14.54B |
| Selling & admin expenses | 2.76B | 2.23B | 2.15B | 2.43B | 2.33B | 2.74B | 2.74B | 2.51B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 9.50B | 10.49B | 10.87B | 11.56B | 11.92B | 11.55B | 11.63B | 12.04B |
| Pretax profit | 9.34B | 766.00M | 6.89B | 3.82B | 7.39B | 10.93B | 13.66B | 9.39B |
| Tax | 2.37B | 2.06B | 2.44B | 1.35B | 1.63B | 2.80B | 2.39B | 2.44B |
| Net profit | 6.97B | -1.30B | 4.45B | 2.48B | 5.76B | 8.13B | 11.26B | 6.95B |
| Basic EPS | 4 | -1 | 2 | 1 | 3 | 5 | 7 | 4 |
| Diluted EPS | 3.68 | -0.70 | 2.40 | 1.34 | 3.19 | 4.57 | 6.54 | 4.12 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 5.26B | 6.10B | 6.07B | 5.85B | 5.43B | 6.11B |
| Gross profit | 3.25B | 3.85B | 3.81B | 3.63B | 3.51B | 3.82B |
| Selling & admin expenses | 588.00M | 619.00M | 580.00M | 720.00M | 550.00M | 663.00M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.66B | 3.23B | 3.23B | 2.91B | 2.96B | 3.16B |
| Pretax profit | 1.68B | 3.12B | 3.08B | 1.51B | 2.86B | 2.93B |
| Tax | 606.00M | 740.00M | 700.00M | 396.00M | 676.00M | 631.00M |
| Net profit | 1.08B | 2.38B | 2.38B | 1.12B | 2.18B | 2.30B |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.63 | 1.41 | 1.41 | 0.67 | 1.30 | 1.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.30B | 4.82B | 7.12B | 6.08B | 7.22B | 5.59B | 4.51B | 5.93B |
| Cash & ST investments | 1.33B | 2.12B | 4.95B | 4.54B | 4.03B | 3.69B | 3.13B | 4.47B |
| Inventory | 2.33B | 2.29B | 1.97B | 1.19B | 1.18B | 1.22B | 1.08B | 1.07B |
| Total assets | 55.46B | 49.27B | 47.41B | 39.52B | 36.95B | 38.57B | 35.18B | 35.02B |
| Total current liabilities | 21.19B | 8.17B | 9.06B | 8.58B | 8.62B | 11.32B | 8.78B | 9.15B |
| Short-term debt | 13.85B | 1.00B | 1.50B | 1.11B | 1.56B | 1.12B | 1.53B | 1.57B |
| Long-term debt | 11.90B | 27.04B | 27.97B | 26.94B | 25.12B | 25.11B | 23.40B | 24.14B |
| Total liabilities | 40,670,000,000.00 | 42,952,000,000.00 | 44,449,000,000.00 | 41,129,000,000.00 | 40,877,000,000.00 | 42,060,000,000.00 | 37,365,000,000.00 | 38,469,000,000.00 |
| Total equity | 14.79B | 6.32B | 2.97B | -1.61B | -3.92B | -3.49B | -2.19B | -3.45B |
| Retained earnings | 43.96B | 36.54B | 34.68B | 30.66B | 29.79B | 31.09B | 35.52B | 35.45B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 6.08B | 2.63B | 5.12B | 5.93B | 5.20B | 4.02B |
| Cash & ST investments | 4.73B | 1.29B | 3.47B | 4.47B | 3.53B | 2.37B |
| Inventory | 1.06B | 1.02B | 1.07B | 1.07B | 1.15B | 1.06B |
| Total assets | 35.76B | 32.33B | 35.01B | 35.02B | 34.58B | 33.37B |
| Total current liabilities | 10.66B | 6.79B | 8.29B | 9.15B | 8.41B | 7.77B |
| Short-term debt | 2.63B | 1.07B | 1.57B | 1.57B | 542.00M | 1.68B |
| Long-term debt | 23.43B | 23.65B | 24.13B | 24.14B | 24.06B | 22.89B |
| Total liabilities | 39,220,000,000.00 | 35,538,000,000.00 | 37,604,000,000.00 | 38,469,000,000.00 | 37,745,000,000.00 | 35,992,000,000.00 |
| Total equity | -3.46B | -3.21B | -2.60B | -3.45B | -3.16B | -2.62B |
| Retained earnings | 34.87B | 35.53B | 36.12B | 35.45B | 35.86B | 36.38B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.39B | 7.84B | 8.39B | 8.41B | 8.26B | 9.29B | 8.75B | 9.29B |
| Depreciation & amortization | 227.00M | 226.00M | 257.00M | 244.00M | 226.00M | 272.00M | 286.00M | 266.00M |
| Free cash flow | 8.15B | 7.59B | 8.15B | 8.24B | 8.05B | 9.09B | 8.61B | 9.07B |
| Dividends paid | -5.42B | -6.07B | -6.29B | -6.45B | -6.60B | -6.78B | -6.85B | -6.96B |
| Stock buybacks / issuance | -1.67B | -845.00M | 0 | -1.68B | -1.83B | -1.00B | -3.40B | -1.00B |
| Ending cash balance | 1.43B | 2.16B | 5.01B | 4.59B | 4.09B | 3.72B | 3.16B | 4.49B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.72B | 205.00M | 3.09B | 3.27B | 2.32B | 719.00M |
| Depreciation & amortization | 71.00M | 71.00M | 70.00M | 54.00M | 56.00M | 56.00M |
| Free cash flow | 2.68B | 173.00M | 3.04B | 3.18B | 2.23B | 662.00M |
| Dividends paid | -1.73B | -1.72B | -1.72B | -1.79B | -1.78B | -1.78B |
| Stock buybacks / issuance | -326.00M | -274.00M | -112.00M | -288.00M | -280.00M | -55.00M |
| Ending cash balance | 4.75B | 1.31B | 3.50B | 4.49B | 3.55B | 2.38B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 46.11 | -12.38 | 98.42 | 399.68 | -- | -- | -- | -- |
| ROA %i | 14.07 | -2.48 | 9.22 | 5.67 | 15.04 | 21.48 | 30.47 | 19.74 |
| ROIC %i | 21.35 | -0.98 | 15.74 | 10.95 | -- | -- | -- | -- |
| 5-year avg ROE %i | 123.93 | 93.09 | 77.27 | 120.87 | -- | -- | -- | -- |
| EBIT margin %i | 51.14 | 10.55 | 38.93 | 23.74 | 41.17 | 58.91 | 72.30 | 52.47 |
| FCF / sales %i | 41.54 | 38.35 | 39.12 | 39.01 | 38.92 | 44.34 | 42.12 | 45.06 |
| Current ratioi | 0.20 | 0.59 | 0.79 | 0.71 | 0.84 | 0.49 | 0.51 | 0.65 |
| Quick ratioi | 0.08 | 0.28 | 0.56 | 0.54 | 0.69 | 0.38 | 0.38 | 0.52 |
| Debt / assetsi | 46.42 | 56.91 | 62.16 | 70.96 | 72.20 | 68.01 | 70.86 | 73.42 |
| LT debt / equityi | 80.46 | 434.62 | 985.24 | -- | -- | -- | -- | -- |
| Interest coveragei | 14.40 | 1.58 | 6.63 | 4.22 | 7.55 | 10.51 | 13.15 | 8.98 |
| Revenue CAGR (3Y) %i | 1.35 | 0.79 | 2.25 | 2.46 | 1.48 | -0.55 | -1.06 | -0.89 |
| Net income CAGR (3Y) %i | 9.93 | -- | -24.11 | -29.16 | -- | 22.09 | 65.72 | 6.42 |
| FCF CAGR (3Y) %i | 13.24 | 27.80 | 20.14 | 0.34 | 1.98 | 3.69 | 1.50 | 4.07 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 28.20 | 26.27 | 25.57 | 19.74 | 22.84 | 24.20 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 67.84 | 58.00 | 58.56 | 52.47 | 57.60 | 56.59 |
| FCF / sales %i | 41.74 | 43.08 | 45.56 | 45.06 | 42.32 | 44.57 |
| Current ratioi | 0.57 | 0.39 | 0.62 | 0.65 | 0.62 | 0.52 |
| Quick ratioi | 0.47 | 0.23 | 0.45 | 0.52 | 0.45 | 0.34 |
| Debt / assetsi | 72.87 | 76.46 | 73.41 | 73.42 | 71.14 | 73.64 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 12.13 | 10.25 | 10.21 | 8.98 | 10.01 | 9.70 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Smokeable products is the largest reported line at 88.23% of revenue, across 3 reported segments.
- The next-largest line, Oral tobacco products, is a distant second at 11.67% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Smokeable products88.23%
Oral tobacco products11.67%
Quote time 2026-10-08 08:19:28 · For reference only, not investment advice and not tailored to your situation.